Welcome to our dedicated page for Atossa Therapeutics SEC filings (Ticker: ATOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Atossa Therapeutics, Inc. (Nasdaq: ATOS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Atossa’s clinical-stage biopharmaceutical operations, centered on the development of its investigational therapy (Z)-Endoxifen for oncology and other serious conditions.
Through forms such as Form 8-K, investors can review Atossa’s reports of material events, including quarterly financial result announcements, changes in executive leadership, regulatory strategy updates, and notices related to Nasdaq listing compliance. Recent 8-K filings describe financial results for specific quarters, the appointment of a new Chief Financial Officer, the release of an updated corporate presentation, and a notice from Nasdaq regarding the minimum bid price requirement and an extension of the compliance deadline.
Filings also document key regulatory and strategic steps, such as press releases incorporated by reference that outline Atossa’s plans for (Z)-Endoxifen in metastatic breast cancer, neoadjuvant ER+/HER2- disease, breast cancer risk reduction, and Rare Pediatric Disease designation for Duchenne Muscular Dystrophy. Additional materials may discuss intellectual property developments, including patents covering enteric oral formulations and methods of using (Z)-Endoxifen.
Stock Titan enhances these SEC filings with AI-powered summaries that aim to clarify the main points of lengthy documents, helping readers quickly identify items related to clinical programs, regulatory milestones, capital markets matters, and corporate governance. Users can also track insider and executive-related disclosures when reported in current reports or other SEC forms.
By reviewing Atossa’s SEC filings alongside AI-generated insights, investors and researchers can better understand the company’s risk factors, development priorities, financial condition, and the formal regulatory record supporting its (Z)-Endoxifen programs.
Atossa Therapeutics, Inc. entered into a new at-the-market equity offering agreement with Rodman & Renshaw LLC, allowing the company to sell up to
Rodman & Renshaw will act as sales agent or principal and earn a commission of up to
The company also terminated its prior Open Market Sale agreement with Jefferies LLC, effective February 19, 2026, incurring no termination penalties and having sold no shares under that earlier arrangement.
Atossa Therapeutics, Inc. has filed a prospectus supplement to sell up to $50,000,000 of its common stock through an at-the-market offering with Rodman & Renshaw LLC under a Sales Agreement. Sales may occur from time to time on Nasdaq or by other permitted methods and Rodman will receive up to a 3.0% commission on gross sales.
The prospectus notes 8,611,428 shares outstanding as of September 30, 2025 and states that all share and per-share amounts in the supplement reflect a 15:1 reverse stock split effective
Atos Therapeutics, Inc. amended its ATM facility. The prospectus supplement states the company reduced the Maximum Offering Price under its Open Market Sale with Jefferies LLC from
No shares have been sold under the ATM Facility as of the date of the supplement.
Atossa Therapeutics, Inc. received notice from Nasdaq on February 17, 2026 that it has regained compliance with the Nasdaq Capital Market’s minimum bid price listing rule. The company’s stock met the requirement to maintain a closing bid price of at least $1.00 per share for 10 consecutive trading days, achieved as of the close on February 13, 2026.
Atossa had previously been notified on February 21, 2025 that it was out of compliance with the $1.00 minimum bid price and was granted an extension through February 17, 2026 to correct the deficiency. With compliance restored, the company’s common stock will continue to be listed and traded on the Nasdaq Capital Market.
Atossa Therapeutics furnished an 8-K to share its 2026 Letter to Shareholders, outlining progress and plans for lead candidate (Z)-endoxifen. The company highlighted a late-2025 FDA Type C meeting that clarified expedited regulatory options in multiple breast cancer settings and ongoing I-SPY 2 neoadjuvant studies, with preliminary combination-therapy data expected in 2026. Atossa obtained Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in Duchenne Muscular Dystrophy, and is exploring additional non-oncology uses. Management paused investment in metastatic breast cancer trials to prioritize higher-return indications, strengthened its leadership team, and reported entering 2026 with more than $40 million in cash and cash equivalents. The company also completed a reverse stock split effective February 2, 2026 to help regain Nasdaq listing compliance.
Atossa Therapeutics President and CEO Steven C. Quay filed an amended Form 4 updating an equity award reported for January 20, 2026. The filing now shows he acquired 331,674 restricted stock units, each representing one share of common stock, vesting one year after the grant date.
Following the transaction, he holds 345,572 common shares directly and 22,254 shares indirectly through Ensisheim Partners, LLC, which he co-owns with Dr. Shu-Chih Chen. The amendment also reports a grant of 950,000 stock options at an exercise price of $0.603, vesting quarterly over 24 months beginning January 20, 2026.
Atossa Therapeutics, Inc. is implementing a 1-for-15 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on February 2, 2026. At that time, each 15 shares of common stock will automatically be combined into one share, and the stock is expected to begin trading on a split-adjusted basis the same day under a new CUSIP, while keeping the ATOS ticker and the $0.18 par value per share.
No fractional shares will be issued; instead, stockholders will receive cash equal to the fractional share multiplied by the closing price of the stock on January 30, 2026, adjusted for the split. The company will make proportional adjustments to outstanding equity awards, plan share reserves, and the conversion terms of its Series B Convertible Preferred Stock. The reverse split was enabled by stockholder approval of an amendment allowing a reverse split in a range of 5:1 to 20:1, with 33,724,885 votes for, 27,888,393 against and 130,938 abstentions, out of 129,171,424 shares entitled to vote as of December 19, 2025.
Atossa Therapeutics President & CEO Steven C. Quay, who also serves as a director, reported new equity awards dated January 20, 2026. He received 325,203 restricted stock units (RSUs), each representing one share of common stock, which will vest one year from the grant date. He was also granted 950,000 stock options with an exercise price of $0.603, vesting quarterly over 24 months following January 20, 2026, contingent on continued service.
Following these awards, Quay directly beneficially owns 339,101 shares of common stock and indirectly holds 22,254 shares through Ensisheim Partners, LLC, an entity he co‑owns with Dr. Shu‑Chih Chen, with shared voting and investment power and a disclaimer of beneficial ownership beyond his pecuniary interest.
Atossa Therapeutics, Inc. released an updated corporate presentation that includes a preliminary estimate of its cash and cash equivalents. The company estimates it held approximately $40 million in cash and cash equivalents as of December 31, 2025.
This cash figure is unaudited, based on internal closing procedures for the fourth quarter and full year 2025, and may change once final results are completed. Atossa stresses that this estimate alone does not provide a full picture of its financial condition or results of operations and cautions investors not to place undue reliance on it.
The presentation also discusses forward-looking expectations for the development and potential regulatory path of the company’s lead program, (Z)-Endoxifen, including possible indications, approval prospects and market opportunities, all of which are subject to significant clinical, regulatory, financing and Nasdaq listing-compliance risks.
Atossa Therapeutics, Inc. reported that on January 6, 2026 the U.S. Food and Drug Administration issued a “Study May Proceed” letter for the company’s study of metastatic breast cancer. This type of letter indicates the FDA has reviewed the planned clinical study and is allowing it to go forward under its current design.
The company disclosed this development through a press release, which is attached as an exhibit to the report. The update highlights progress in Atossa’s efforts to clinically evaluate its approach in patients with metastatic breast cancer, an advanced stage of the disease where new treatment options are often needed.